|Mr. Matthew Craig Kapusta||CEO & Exec. Director||969.95k||N/A||1972|
|Mr. Christian Klemt||CFO, Principal Financial Officer & GM of Amsterdam Site||505.02k||N/A||1973|
|Mr. Pierre Caloz||Chief Operating Officer||714k||N/A||N/A|
|Dr. Alexander E. Kuta Ph.D.||Exec. VP of Quality & Regulatory Affairs||649.26k||1.42M||1960|
|Dr. Ricardo Dolmetsch Ph.D.||Pres of R&D||795.35k||N/A||1969|
|Prof. Hugo Katus||Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany||N/A||N/A||N/A|
|Mr. David Cerveny||Chief Legal Officer, Gen. Counsel & Sec.||N/A||N/A||1967|
|Dr. Tamara Tugal Ph.D., MBA||Bus. Devel. Director||N/A||N/A||N/A|
|Ms. Erin Boyer||Chief People & Culture Office||N/A||N/A||N/A|
|Ms. Maria E. Cantor||Chief Corp. Affairs Officer||N/A||N/A||1968|
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
uniQure N.V.’s ISS governance QualityScore as of 1 October 2022 is 3. The pillar scores are Audit: 8; Board: 3; Shareholder rights: 2; Compensation: 3.